Kezar Life Sciences Shares Are Trading Higher After the Company Announced the Voluntary Cessation in Enrollment of New Patients and Dosing of Ongoing Patients in the Phase 2b PALIZADE Clinical Trial, Pending Further Evaluation.
Kezar Life Sciences Shares Are Trading Higher After the Company Announced the Voluntary Cessation in Enrollment of New Patients and Dosing of Ongoing Patients in the Phase 2b PALIZADE Clinical Trial, Pending Further Evaluation.
kezar life sciences股價上漲，因公司宣佈自願停止在20億PALIZADE臨床試驗中招募新患者和對正在接受治療的患者進行投藥，等待進一步評估。
Kezar Life Sciences Shares Are Trading Higher After the Company Announced the Voluntary Cessation in Enrollment of New Patients and Dosing of Ongoing Patients in the Phase 2b PALIZADE Clinical Trial, Pending Further Evaluation.
kezar life sciences股價上漲，因公司宣佈自願停止在20億PALIZADE臨床試驗中招募新患者和對正在接受治療的患者進行投藥，等待進一步評估。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。